MetaBlok™

Potential treatment for inflammation and cancer metastasis

MetaBlok TM

MetaBlok is a new drug candidate and potential treatment for inflammation, sepsis and cancer metastasis.

Arch is currently pursuing clinical development of Metablok to prevent acute kidney injury caused by inflammation and expects to make additional disclosures as milestones toward a phase II...

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage

TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr. Stephen Robbins and Dr. Paul Kubes at the...

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver

Authors

Saurav Roy Choudhury, Liane Babes, Jennifer J. Rahn, Bo-Young Ahn, Kimberly-Ann R. Goring, Jennifer C. King, Arthur Lau, Björn Petri, Xiaoguang Hao, Andrew K. Chojnacki, Ajitha Thanabalasuriar, Erin F. McAvoy, Sébastien Tabariès, Christoph...

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™ and MetaMx™

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is currently a Professor at the University of Calgary in the Departments of Oncology and Biochemistry & Molecular Biology. He is a former Canada Research Chair...

AB569

Drug candidate for treating antibiotic resistant infections

AB569: Treatment for Drug Resistant Bacterial Infections

AB569 is a new drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. It also has potential to be modified for use in...

AB569 Principal Scientist

Lead scientist for AB569 which targets Respiratory Pseudomonas Infections

[yjsgimgs image="images/arch_content_images/headshots/drHasset.png" class="" title="" link="" target="" effect="none"]

Dr. Hassett

Dr. Hassett is a Professor in the Department of Molecular Genetics, Biochemistry and Microbiology...

    Bridging the gap between science and business

    Bringing new medical innovation to market.

    Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual...

    Stock information

    Arch Biopartners trades as ARCH:TSXV in Canada, and ACHFF:OTCBB in the United States.

    Management and Board of Directors

    Investor Relations and Investor Information